AU2018348929B2 - Semaglutide in medical therapy - Google Patents

Semaglutide in medical therapy Download PDF

Info

Publication number
AU2018348929B2
AU2018348929B2 AU2018348929A AU2018348929A AU2018348929B2 AU 2018348929 B2 AU2018348929 B2 AU 2018348929B2 AU 2018348929 A AU2018348929 A AU 2018348929A AU 2018348929 A AU2018348929 A AU 2018348929A AU 2018348929 B2 AU2018348929 B2 AU 2018348929B2
Authority
AU
Australia
Prior art keywords
semaglutide
subject
administered
sema
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018348929A
Other languages
English (en)
Other versions
AU2018348929A1 (en
Inventor
Thomas Hansen
Maria KABISCH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60083831&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2018348929(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of AU2018348929A1 publication Critical patent/AU2018348929A1/en
Application granted granted Critical
Publication of AU2018348929B2 publication Critical patent/AU2018348929B2/en
Priority to AU2025203535A priority Critical patent/AU2025203535A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2018348929A 2017-10-12 2018-10-10 Semaglutide in medical therapy Active AU2018348929B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025203535A AU2025203535A1 (en) 2017-10-12 2025-05-15 Semaglutide in medical therapy

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17196254.1 2017-10-12
EP17196254 2017-10-12
PCT/EP2018/077654 WO2019072941A1 (en) 2017-10-12 2018-10-10 SEMAGLUTIDE IN MEDICAL THERAPY

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025203535A Division AU2025203535A1 (en) 2017-10-12 2025-05-15 Semaglutide in medical therapy

Publications (2)

Publication Number Publication Date
AU2018348929A1 AU2018348929A1 (en) 2020-05-07
AU2018348929B2 true AU2018348929B2 (en) 2025-02-27

Family

ID=60083831

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018348929A Active AU2018348929B2 (en) 2017-10-12 2018-10-10 Semaglutide in medical therapy
AU2025203535A Pending AU2025203535A1 (en) 2017-10-12 2025-05-15 Semaglutide in medical therapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025203535A Pending AU2025203535A1 (en) 2017-10-12 2025-05-15 Semaglutide in medical therapy

Country Status (18)

Country Link
US (4) US12029779B2 (enExample)
EP (1) EP3694538A1 (enExample)
JP (2) JP7148605B2 (enExample)
KR (1) KR20200069316A (enExample)
CN (4) CN120241968A (enExample)
AU (2) AU2018348929B2 (enExample)
BR (1) BR112020006246A2 (enExample)
CA (1) CA3078652A1 (enExample)
CL (1) CL2020000812A1 (enExample)
IL (3) IL322969A (enExample)
MA (1) MA50358A (enExample)
MX (3) MX2020003049A (enExample)
MY (1) MY204827A (enExample)
PH (1) PH12020550185A1 (enExample)
SG (1) SG11202002841PA (enExample)
TW (1) TWI842681B (enExample)
WO (1) WO2019072941A1 (enExample)
ZA (3) ZA202503388B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL322969A (en) * 2017-10-12 2025-10-01 Novo Nordisk As Semaglutide in medical therapy
WO2021162532A2 (ko) 2020-02-14 2021-08-19 주식회사 지투지바이오 Glp-1 유사체, 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 미립구를 포함하는 약학적 조성물
PE20221575A1 (es) * 2020-02-18 2022-10-06 Novo Nordisk As Formulaciones farmaceuticas
US11478533B2 (en) * 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
EP4313016A4 (en) * 2021-03-29 2025-01-22 Sanford Health METHODS AND COMPOSITIONS FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES
EP4536691A1 (en) * 2022-06-08 2025-04-16 Zydus Lifesciences Limited Reusable multi-dose, variable dose, single pen injector for type 2 diabetes and weight management
WO2024249659A2 (en) * 2023-05-30 2024-12-05 The Medical College Of Wisconsin, Inc. Methods for weight loss and/or reducing weight gain
WO2024252134A1 (en) * 2023-06-05 2024-12-12 Closed Loop Medicine Ltd Dosing of incretin pathway drugs

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014005858A1 (en) * 2012-07-01 2014-01-09 Novo Nordisk A/S Use of long-acting glp-1 peptides

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US20030119734A1 (en) 2001-06-28 2003-06-26 Flink James M. Stable formulation of modified GLP-1
KR101241862B1 (ko) 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 ｇｌｐ-1 유도체
PT1687019T (pt) 2003-11-20 2018-02-26 Novo Nordisk As Formulações de péptidos que contêm polietileno glicol que são ótimas para produção e para utilização em dispositivos de injeção
EP2494983B1 (en) 2004-11-12 2019-04-24 Novo Nordisk A/S Stable formulations of glp-1
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
AU2006290227B2 (en) 2005-09-14 2012-08-02 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
WO2007121411A2 (en) 2006-04-14 2007-10-25 Mannkind Corporation Glucagon-like peptide 1(glp-1) pharmaceutical formulations
CN101631548B (zh) 2007-01-31 2014-08-27 比艾尔-坡特拉有限公司 Comt抑制剂的单次药物剂量单元和药物组合物
US20100047762A1 (en) 2007-03-20 2010-02-25 Nippon Kayaku Kabushiki Kaisha Method to monitor drug efficacy in diabetic patients using an assay for 1,5-anhydro-d-glucitol
WO2009030774A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Truncated glp-1 derivatives and their therapeutical use
DK2373681T3 (en) 2008-12-10 2017-04-24 Glaxosmithkline Llc PHARMACEUTICAL COMPOSITIONS OF ALBIGLUTID
NZ619520A (en) 2009-02-13 2015-06-26 Boehringer Ingelheim Int Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
CA2784757A1 (en) 2009-12-16 2011-07-07 Novo Nordisk A/S Double-acylated glp-1 derivatives
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
WO2012016419A1 (zh) 2010-08-06 2012-02-09 浙江贝达药业有限公司 Glp-1衍生物及其应用
PL2651398T3 (pl) 2010-12-16 2018-05-30 Novo Nordisk A/S Stałe kompozycje zawierające agonistę GLP-1 i sól kwasu N-(8-(2-hydroksybenzoilo)amino)kaprylowego
CA2822617A1 (en) 2010-12-22 2012-06-28 Marcadia Biotech, Inc. Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN102718858B (zh) 2011-03-29 2014-07-02 天津药物研究院 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
WO2012136790A1 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
CN102229668A (zh) 2011-06-03 2011-11-02 浙江贝达药业有限公司 一种glp-1衍生物及其应用
WO2012177929A2 (en) 2011-06-24 2012-12-27 Amylin Pharmaceuticals, Inc. Methods for treating diabetes with extended release formulations of glp-1 receptor agonists
JP6280501B2 (ja) 2011-09-08 2018-02-14 メレオ バイオファーマ ２ リミテッド 性腺機能低下症および関連疾患の処置ためのアロマターゼ阻害剤の使用
EP2846823B1 (en) 2012-05-08 2019-12-04 Novo Nordisk A/S Double-acylated glp-1 derivatives
CA3067012C (en) 2012-06-29 2021-10-05 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
KR20210086717A (ko) * 2013-05-02 2021-07-08 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
CR20180378A (es) 2015-12-23 2018-12-06 Amgen Inc Método para tratar o mejorar trastornos metabólicos con proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agosnistas de glp-1
US10813918B2 (en) 2017-08-04 2020-10-27 Ovid Therapeutics Inc. Use of Gaboxadol in the treatment of diabetes and related conditions
IL322969A (en) 2017-10-12 2025-10-01 Novo Nordisk As Semaglutide in medical therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014005858A1 (en) * 2012-07-01 2014-01-09 Novo Nordisk A/S Use of long-acting glp-1 peptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "NCT02453711 on 2017_07_26: ClinicalTrials.gov Archive", 26 July 2017 (2017-07-26), XP055445268, Retrieved from the Internet [retrieved on 20180126] *

Also Published As

Publication number Publication date
CN111212657A (zh) 2020-05-29
US12029779B2 (en) 2024-07-09
SG11202002841PA (en) 2020-04-29
MX2025002189A (es) 2025-04-02
US20240415935A1 (en) 2024-12-19
CN120241968A (zh) 2025-07-04
US20250235511A1 (en) 2025-07-24
JP7475398B2 (ja) 2024-04-26
BR112020006246A2 (pt) 2021-03-30
US12551536B2 (en) 2026-02-17
JP2020536854A (ja) 2020-12-17
MX2025002188A (es) 2025-04-02
WO2019072941A1 (en) 2019-04-18
EP3694538A1 (en) 2020-08-19
CA3078652A1 (en) 2019-04-18
US20240316159A1 (en) 2024-09-26
CN119838000A (zh) 2025-04-18
RU2020114960A (ru) 2021-10-28
KR20200069316A (ko) 2020-06-16
ZA202503388B (en) 2025-09-25
ZA202503350B (en) 2025-09-25
US12295988B2 (en) 2025-05-13
IL322969A (en) 2025-10-01
AU2025203535A1 (en) 2025-06-05
CL2020000812A1 (es) 2020-08-14
CN119950682A (zh) 2025-05-09
IL322968A (en) 2025-10-01
PH12020550185A1 (en) 2021-03-01
IL273470A (en) 2020-05-31
MX2020003049A (es) 2020-07-27
RU2020114960A3 (enExample) 2022-02-11
ZA202503387B (en) 2025-09-25
AU2018348929A1 (en) 2020-05-07
MA50358A (fr) 2020-08-19
MY204827A (en) 2024-09-18
TW201914611A (zh) 2019-04-16
TWI842681B (zh) 2024-05-21
US20200237876A1 (en) 2020-07-30
JP7148605B2 (ja) 2022-10-05
JP2022132414A (ja) 2022-09-08

Similar Documents

Publication Publication Date Title
US12295988B2 (en) Semaglutide in medical therapy
EA034940B1 (ru) Лечение пациентов с сахарным диабетом 2 типа
US20240100127A1 (en) Tirzepatide therapeutic methods
TW202417035A (zh) 提派肽(tirzepatide)組合物及用途
RU2800651C2 (ru) Семаглутид в лекарственной терапии
WO2021224338A1 (en) Treatment of hyperuricemia
US20250360183A1 (en) Use of gmi from ganoderma lucidum spores in the preparation of pharmaceuticals and food products
Damasceno et al. Eculizumab or ravulizumab treatment effect in people with neuromyelitis optica spectrum disorder: a plain language summary of three studies
BR122025013280A2 (pt) Uso de semaglutida para fabricar uma solução injetável subcutânea para tratar diabetes tipo 2
US20260053769A1 (en) Uses of selective androgen receptor modulator (sarm) compounds for quality weight loss
BR122024015868A2 (pt) Uso de semaglutida para preparação de uma composição farmacêutica para tratamento e/ou prevenção de obesidade e/ou de sobrepeso
BR122024015864A2 (pt) Uso de semaglutida para preparação de uma composição farmacêutica para controle de peso
CN121969358A (zh) 选择性雄激素受体调节剂（sarm）化合物在长期体重管理中的用途
Doknic et al. MON-LB56 Metabolic Profile in 107 Patients With Childhood Onset Growth Hormone Deficiency (CO-GHD) at the Time of Transition From Pediatric to Adulthood Endocrine Care
CN113727996A (zh) 重组蛋白用于治疗代谢疾病

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)